102 related articles for article (PubMed ID: 7537602)
1. Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia.
Eri LM; Haug E; Tveter KJ
Br J Urol; 1995 Mar; 75(3):335-40. PubMed ID: 7537602
[TBL] [Abstract][Full Text] [Related]
2. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
[TBL] [Abstract][Full Text] [Related]
3. Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
Eri LM; Urdal P
Eur Urol; 1995; 27(4):274-9. PubMed ID: 7544732
[TBL] [Abstract][Full Text] [Related]
4. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
Eri LM; Haug E; Tveter KJ
Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
[TBL] [Abstract][Full Text] [Related]
5. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
Eri LM; Tveter KJ
J Urol; 1993 Jul; 150(1):90-4. PubMed ID: 7685428
[TBL] [Abstract][Full Text] [Related]
6. New alternative treatment in hirsutism: bicalutamide 25 mg/day.
Müderris II; Bayram F; Ozçelik B; Güven M
Gynecol Endocrinol; 2002 Feb; 16(1):63-6. PubMed ID: 11915584
[TBL] [Abstract][Full Text] [Related]
7. Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
Lunglmayr G
Horm Res; 1989; 32 Suppl 1():77-81. PubMed ID: 2515147
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat.
Chandolia RK; Weinbauer GF; Simoni M; Behre HM; Nieschlag E
Acta Endocrinol (Copenh); 1991 Nov; 125(5):547-55. PubMed ID: 1759544
[TBL] [Abstract][Full Text] [Related]
9. Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.
Eri LM; Tveter KJ
Eur Urol; 1994; 26(3):219-26. PubMed ID: 7528662
[TBL] [Abstract][Full Text] [Related]
10. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
Siegberg R; Nilsson CG; Stenman UH; Widholm O
Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
[TBL] [Abstract][Full Text] [Related]
11. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
[TBL] [Abstract][Full Text] [Related]
12. Clinical profile of a new non-steroidal antiandrogen.
Mahler C; Denis L
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):921-4. PubMed ID: 2126736
[TBL] [Abstract][Full Text] [Related]
13. Endocrine effects of vasectomy.
Purvis K; Saksena SK; Cekan Z; Diczfalusy E; Giner J
Clin Endocrinol (Oxf); 1976 May; 5(3):263-72. PubMed ID: 133774
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
Cónsole GM; Jurado SB; Rulli SB; Calandra RS; Gómez Dumm CL
Cells Tissues Organs; 2001; 169(1):64-72. PubMed ID: 11340263
[TBL] [Abstract][Full Text] [Related]
15. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
[TBL] [Abstract][Full Text] [Related]
16. Effects of tamoxifen on the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), 17 beta-oestradiol (E2), total and free testosterone (T) and total and free dihydrotestosterone (DHT) in blood of patients with benign prostatic hyperplasia.
Stahl F; Schnorr D; Rohde W; Poppe I; Geier T; Dörner G
Exp Clin Endocrinol; 1983 Jul; 82(1):21-8. PubMed ID: 6193975
[TBL] [Abstract][Full Text] [Related]
17. Effects of androgens and antiandrogens on the quantitative immunohistochemistry of gonadotrope cells in prepubertal male rats.
Cónsole GG; Rulli SB; Riccillo FL; Calandra RS; Gómez Dumm CL
Neuroendocrinology; 1999 Oct; 70(4):261-7. PubMed ID: 10529621
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
Katayama T; Umeda K; Kazama T
Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
[TBL] [Abstract][Full Text] [Related]
19. The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women.
Sir-Petermann T; Rabenbauer B; Wildt L
Hum Reprod; 1993 Nov; 8(11):1807-12. PubMed ID: 8288741
[TBL] [Abstract][Full Text] [Related]
20. Endocrine consequences of danazol treatment in menorrhagia.
Guoth J; Olajos F; Zsolnai B
Eur J Obstet Gynecol Reprod Biol; 1986 Oct; 23(1-2):79-83. PubMed ID: 2946616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
